Kornimate/medical-research-clean huggingface dataset:
a novel carbohydrate counting smartphone app for youth with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: type 1 diabetes mellitus (t1dm) is a common chronic disease of childhood. t1dm has substantial impact on quality of life (qol), including burdensome dietary restrictions and the need to count carbohydrates in foods to safely dose insulin. carbohydrate counting is challenging, inconvenient, and, if done wrong, can cause high or low blood glucose levels. to address these challenges, ispy, a novel smartphone application, was created to identify foods and determine their carbohydrate content using pictures or speech. this pilot study is to evaluate if using ispy improves carbohydrate counting accuracy and efficiency. pilot participants will have carbohydrate counting (accuracy and efficiency) and their overall qol (with respect to carbohydrate counting) assessed at baseline and after 3-months. the investigators hypothesize that using ispy will make carbohydrate counting easier (by improving accuracy and efficiency) and enhance qol for patients and/or their caregivers. if so, ispy may help lessen the burden of living with t1dm.

nutrition is an integral component of management of many chronic diseases and of overall wellness. helping individuals to understand what they are eating can empower them to better manage their diseases. for example, the growing number of youth living with type 1 diabetes mellitus (t1dm) struggle with carbohydrate counting, an essential and daily aspect of their lives, because of required reliance on memorization and numeracy skills. effective carbohydrate counting has been demonstrated to improve blood glucose control, while inaccurate carbohydrate counting results in more variable blood glucose. concerns related to carbohydrate counting accuracy can also limit food choices, provoke anxiety, and decrease quality of life. since there is no cure for t1dm, enhancing patients' ability to understand and apply carbohydrate counting is an important part in helping them manage their condition most effectively. ispy is a novel healthcare application that addresses an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.

Eligibility criteria:
inclusion criteria: * diagnosed with t1dm for ≥6 months; * completion of initial carbohydrate counting classes; * incorporating carbohydrate counting into treatment regimen; * having access to a smart phone and data plan; exclusion criteria: * cognitive impairments or co-morbid physical or psychiatric condition (e.g. blindness, clinical depression, anxiety disorder) that might impact ability to use ispy; * diagnosis of condition that affects dietary exposure (e.g. celiac disease); * participation in usability study;
the effect of broccoli sprout extract and probiotics for eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: in korea, the first-line therapy to treat helicobacter pylori (hp) consists of a proton pump inhibitor (ppi) and two antibiotics for one week. but, eradication has become less successful due to low compliance and high resistance to the antibiotics. therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. in vitro study, we previously reported that a broccoli sprout extract containing sulforaphane may prevent lipid peroxidation in the gastric mucosa and play a cytoprotective role in hp-induced gastritis. also, several studies suggested that probiotics could be effective for improving hp eradication rate or reducing adverse events. but, their effect for eradication of hp is not yet conclusive. the aims of this prospective study is to investigate the efficacy of a broccoli sprout extract containing sulforaphane and probiotics for eradication of hp, compared with standard triple therapy.


Eligibility criteria:
inclusion criteria: * helicobacter pylori infected patients * patients with active or healing gastric/duodenal ulcers exclusion criteria: * prior hp eradication therapy * previous gastric resection * previous use of proton pump inhibitors, bismuth, h2 receptor antagonist or antibiotics within 4 weeks of the study * patients who were pregnant or lactating

Keywords: helicobacter pylori probiotics sulforaphane
comparing clinical outcomes of suture button versus fibulink fixation for acute ankle syndesmosis injuries

Conditions: Ankle Injuries; Syndesmotic Injuries; Ankle Fractures

Summary: this project consists of a randomized controlled study design. study candidates will include all patients 18 years or older, who were evaluated at ucsd and found to have an acute ankle syndesmosis injury requiring surgery. patients who consent to study participation will be randomized to receive one of two standard of care procedures - either a suture button or fibulink implant. outcome measures, including the olerud-molander and american orthopaedic foot and ankle society scores, pain, range of motion, time to return to work, and radiographic evaluation will be collected for each participant. given the potential degenerative changes and poor radiographic and clinical outcomes with inadequate repair of the syndesmosis, it is imperative to evaluate existing and emerging methods of fixation for patients with acute ankle fractures with syndesmosis injuries.


Eligibility criteria:
inclusion criteria: * ankle fracture with associated syndesmotic injury requiring surgery * age 18 years or older * ability to understand the content of the patient information/informed consent form exclusion criteria: * any not medically managed severe systemic disease * patient preference for specific implant * refusal of randomization * pregnant patients * prisoners * participation in any other pharmacologic or medicinal product study within the previous month that could influence the results of this study
evaluation of efficacy of zoledronic acid in patients with haemoglobin syndromes (thalassemia and sicle cell anaemia) and risk of skeletal events

Conditions: Thalassemia

Summary: the evaluation of efficacy is performed by laboratory monitoring of bone density and resorption markers and clinical monitoring of bone density improvement. this is a prospective, randomized, parallel group, single blind study of one year treatment with zoledronic acid every 6 months as compared to one year treatment with zoledronic acid every 3 months and to placebo every 3 months in patients with hemoglobin syndromes and risk of skeletal complications.


Eligibility criteria:
inclusion criteria: * patients with thalassaemia or sickle cell anaemia and bone density, z-scores \< -1.5, in at least one of the examined sites * normal renal function. urea and creatinine should not exceed \> 2-fold the upper limit of normal (\< 2 x uln). exclusion criteria: - other protocol-defined inclusion / exclusion criteria may apply.

Keywords: thalassemia zoledronic acid skeletal events
a prospective randomized phase ii study evaluating the monitoring of imatinib mesylate plasmatic through level in patients newly diagnosed with cp-cml

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Summary: imatinib mesylate (gleevec/glivec, im) is currently the gold standard or cml-cp front line therapy. the recommended dose of im is 400 mg/day. the rates of complete cytogenetic responses at 3, 6 and 12 months are 27%, 50% and 69% respectively. the optimal im daily dose is not yet determined and randomized studies addressing this question are on-going. first results from the tops trial (eha 2008 congress) suggest a more rapid kinetic of response for patients treated with imatinib high dose. recent studies revealed that initial imatinib plasmatic dosage is predictive for achieving complete cytogenetic responses (ccr) and that a dosage of 1000 ng/ml is associated with a higher proportion of major molecular responses (mmr) (picard et al., blood 2007, larson et al. blood 2007). results from the study of larson et al. indicate that around 40% of the patients had a trough plasmatic level below 1000 ng/ml after day 28 of imatinib 400 mg/d. the major molecular response rate at 12 months for the patients with the lower plasmatic through level is 25.4% compared to 40.1% for the patients with a plasmatic dosage over 800 to 1000 ng/ml. investigators propose to adapt the imatinib daily dose in case of imatinib through plasmatic level at day 28 below 1000 ng/ml. patients with a trough plasmatic dosage ≤ 1000 ng/ml will be randomized between a prospective adaptation strategy of the imatinib daily dose (cohort 1) versus observation only (cohort 2). the patients with adequate imatinib dosage (\> 1000 ng/ml) will be followed up according the eln recommendation (cohort 3). imatinib trough plasmatic level will then be rechecked every month thereafter for patients in cohort 1 and cohort 2 and every three months in cohort 3. the first endpoint of the study will be the rate of major molecular response at 12 months in cohort 1. our hypothesis is to improve the 12 months mmr rate with the optimized strategy (cohort 1) from 25% of mmr at 12 months to 40% of mmr at 12 months.


Eligibility criteria:
inclusion criteria: 1. male or female patient ≥ 18 years 2. philadelphia chromosome positive newly diagnosed chronic myelogenous leukaemia (≤ 4 months) in first chronic phase. 3. not previously treated with tyrosine kinase inhibitors other than imatinib 4. prior treatment with imatinib during less than 13 weeks 5. signed written inform consent 6. women of childbearing potential (wocbp) must be using an adequate method of contraception exclusion criteria: 1. patients with bcr-abl positive, philadelphia negative cml 2. patient previously treated with tki other than imatinib 3. pregnancy 4. active malignancy 5. concurrent severe diseases which exclude the administration of therapy
study of u101 for bladder pain and/or urgency

Conditions: Pelvic Pain; Interstitial Cystitis; Bladder Diseases

Summary: the purpose of this study is to determine whether intravesical u101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.


Eligibility criteria:
inclusion criteria: * male and female subjects at least 18 years of age. * subjects must have given written informed consent to participate in this trial. * all female subjects, except those who are post-menopausal and/or surgically sterilized, must consent to use two medically acceptable methods of contraception throughout the entire study period. medically acceptable methods of contraception that may be used by the subject and/or her partner include: abstinence, birth control pills, diaphragm with spermicide, intrauterine device (iud), condom and foam, vaginal spermicidal suppository, progestin implant, and depo-provera injections. * subjects must have had symptoms of pelvic pain and/or urgency. * medical history and physical examination results must be clinically acceptable to the investigator. medical monitor may evaluate subjects who don't meet eligibility criteria. * female subjects currently using hormone therapy (ht) must have been using ht for at least 3 months. exclusion criteria: * subjects less than 18 years of age. * subjects with known hypersensitivity to heparin or lidocaine. * female subjects who have a positive pregnancy test at the time of screening, who are pregnant or lactating, or who are planning to become pregnant during the study period. * subjects who are chronic users of narcotics or who are using any narcotics at the time of study entry. * subjects who have hepatic disease or clinically significant abnormal liver function tests (more than twice the upper limit of the normal range). * subjects who do not expect to be available for the entire duration of the study. * subjects with any coexisting significant medical condition that is likely to interfere with study procedures (cardiovascular, hematological, central nervous system, pulmonary, renal, etc.) * subjects who have been treated with dimethyl sulfoxide (dmso) or other bladder instillation therapies within three months prior to study entry. * subjects who have had cystoscopic dilatation of their bladder or urethra within three months of study entry. * subjects who have taken or used any investigational drug or device within 30 days before the start of the study, or who are currently enrolled in another investigational study. * subjects contemplating having or scheduled for any invasive surgical procedures during the study period. * subjects who are unwilling or unable to abide by the requirements of the study. * history of gastrointestinal (gi) bleeding * active bleeding from any source * screening activated partial thromboplastin time (aptt) above normal limits * systolic blood pressure (bp) \> 180 mmhg or \< 90 mmhg at screening. * subjects with an actively bleeding lesion/area in the bladder as detected by urinalysis

Keywords: interstitial cystitis pelvic pain urgency frequency pelvic pain and/or urgency of bladder origin
promoting dignity, meaningfulness and mental well-being

Conditions: Life-limiting Serious Illness

Summary: feasibility study to test the feasibility and acceptability of a designed personalized modular intervention consisting of three modules, including cancer and living meaningfully (calm) therapy, dignity therapy (dt), and a mindfulness-based intervention

patient with a life-limiting serious illness commonly experience substantial emotional and spiritual distress, death anxieties, depressive symptoms and loss of dignity and purpose in life. fostering dignity and meaning and relieving psychological distress have been identified as a core objective for end-of-life care. however, individual's needs for dignity and psychological support at the end of life may vary. therefore, a personalized approach is needed. on the basis of theoretical frameworks and existing dignity- fostering and meaning- based interventions, as well as an one-day workshop with international experts in the field of palliative care, a personalized modular intervention, consisting of three modules, including calm therapy, dignity therapy, and a mindfulness-based intervention, was developed.

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * patients in palliative situation (i.e. patients suffering from an advanced, incurable, life-limiting disease with multimodal support needs) * estimated life expectancy ≤ 18 months * patients seen by the palliative consultation-liaison service at the university hospital basel as an in- or outpatient * willingness and capacity to commit at least three contacts over about 7-10 days exclusion criteria: * being delirious or otherwise substantially cognitively impaired (based on clinical consensus) * being too ill to complete the requirements of the study protocol * unable to understand and speak german

Keywords: calm therapy dignity therapy mindfulness-based intervention personalized modular intervention
neuromuscular electrical stimulation with and without constraint induced movement therapy in erb's palsy

Conditions: Erb's Palsy

Summary: erb's duchenne paralysis constitutes the single commonest form of brachial plexus injury, brachial plexus injury (bpi) is unfortunately a rather common injury in newborn children. incidence varies between 0.15 and 3 per 1000 live births in various series and countries. the constraint-induced movement therapy (cimt) has been used to promote functional gains in individuals with neurological dysfunctions .the constraint-induced movement therapy consists of constraining movement of the non-affected upper extremity and providing intensive training to the involved upper extremity. neuromuscular electrical stimulation (nmes) has been used for muscle strengthening, maintenance of muscle mass and strength during prolonged periods of immobilisation, selective muscle retraining, and the control of oedema.the aim of this study is to compare the effects of neuromuscular electrical stimulation with and without constraint induced movement therapy on upper limb function in children with erb's palsy. it is a randomized controlled trial.the sample size calculated by using openepi or gpower. data will be collected from jinnah hospital,children hospital,lahore medical city hospital,farooq hospital,rising sun institute and psrd. the patients will be selected through non-probability convenience sampling,will be divided into two groups. the group a will receive habituation exercises for six weeks, three times per week for thirty minutes, along with application of neuromuscular electrical stimulation for a period of 6 weeks four times a week and perform constrained induced movement therapy techniques, each for 8 weeks.the interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.. the group b will be given neuromuscular electrical stimulation for a period of 6 weeks four times a week.range of motion ,flexibility exercises will be given as baseline treatment to both groups. the arm function was evaluated by the mallet score system, while active abduction and external rotation range of motion were measured by a standard universal goniometer. data will be analyzed by spss 25.


Eligibility criteria:
inclusion criteria: * aged between 2.5 to 8 years years * clinically diagnosed with erb's palsy/brachial plexus palsy * ability to cooperate with assessments and therapy * full passive roms in all motions at the shoulder, elbow, and wrist joints exclusion criteria: * cognitive impairment * contracture in the affected upper extremity * injured unaffected arm * visual problems likely to interfere with treatment/testing * previous orthopedic or neurological surgery * previous application of cimt
variable negative external pressure (vnep) - an alternative to continuous positive airway pressure (cpap) for the treatment of obstructive sleep apnea (osa): a pilot study

Conditions: Obstructive Sleep Apnea

Summary: non-compliance rates estimated at 50% pose a major issue for cpap therapy, the primary treatment for osa. negative external pressure, applied over the anterior neck under the mandible, has shown encouraging results as an alternative therapy. this study assessed a variety of sizes and shapes of collars and a range of pressures for variable negative external pressure (vnep) treatment in subjects having moderate osa to identify combinations that improve the efficacy and comfort of this emerging therapy. observations made in this study may be used to plan a more definitive follow-on investigation.


Eligibility criteria:
inclusion criteria: * a polysomnogram study or home sleep test within the previous six months that shows either an ahi \> 15 and ahi \<= 30 * able, in the opinion of the investigator, to understand and comply with all study procedures * the vnep collar is determined by the investigator to properly fit the subject and is well-tolerated after application to the neck.

Keywords: negative pressure variable negative external pressure
remifentanil infusion alone during the closure period for early emergence following craniotomy

Conditions: Supratentorial Neoplasms

Summary: total intravenous anaesthesia using propofol and remifentanil are routinely used drugs for this purpose. the hemodynamic stability and at the same time early emergency are the main goals following neurosurgery. however there is no standard for discontinuation time for manually controlled systems today. the investigators aimed to study the effect of remifentanil infusion alone for early emergence and hemodynamic stability during the closure period in patients undergoing supratentorial craniotomy.

adult, american society of anaesthesiologist score i-ii, 80 patients who underwent elective supratentorial craniotomy for tumour resection were randomly assigned to group i or ii. in group i; propofol was discontinued during the dural closure. after the propofol was discontinued, remifentanil dose was increased with the guidance of bispectral index spectrum and hemodynamic parameters. in group ii; propofol discontinued before the end of the surgery. time to awakening and extubation time, adverse events, total remifentanil and propofol consumptions and side effects were recorded. heart rate and blood pressure were recorded during this period.

Eligibility criteria:
inclusion criteria: * american society of anaesthesiologist physical status i-ii * glasgow coma scale score of 15 points * elective supratentorial craniotomy for tumor resection * supine position exclusion criteria: * obese patient * brain tumor greater than 30 mm in diameter * postoperative cranial drainage * hypertension * diabetes mellitus * reoperation * pregnant * breast feeding * allergy to the study medications * history of cranial radiotherapy * frontal bone flap * intraoperative neuromonitoring
light therapy in parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease, a degenerative disorder of the dopaminergic system, combines motor symptoms but also non-motor, such as depression, sleep disorders and circadian rhythms and impaired cognitive functions. difficulties in balancing the dopaminergic treatment of these patients emphasizes the need to find effective adjuvant therapies. light therapy (lt) represents one such innovative therapeutic approach. although light has an obvious to visual pathways within the brain, today it is known to additionally exert non-visual effects throughout the body. recently our team has shown that non-visual, non-circadian light plays a major role in the regulation of sleep, as well as cognitive brain function in general. the retina, the primary conduit for the transmission of light information is weakened or thinned in parkinson's patients. the dopamine system is known to enhance the processing of light information and intraocular injection of l-dopa in animal models of parkinson's disease, can reverse associated motor symptoms. this allows for the possibility that lt would strengthen the dopaminergic tone in the central nervous system. however, to this date its effectiveness for alleviating parkinson's symptoms has only been suggested by two studies, both poorly controlled. thus, through the convergence of basic and clinical data, a study examining the effect of lt directly in people parkinson's disease symptoms, whilst controlling for the effects on sleep, circadian system, mood, and cognitive functioning, is of extreme importance. with this information our hope is to determine if these polymorphisms allow for a predictive model of response to lt treatment.


Eligibility criteria:
inclusion criteria: * idiopathic parkison's disease, low or moderately severe * hoehn\&yahr \<4 * 4 to \< 15 years of evolution· * between 45-75 years old * absence of dementia : mmse \> 23· * no severe depression * stable medication levels during the 5 weeks before inclusion exclusion criteria: * secondary or severe parkinson's disease * ocular pathologies (i.e. retinopathy) * photosensitive medication * antidepressant treatment· * major depression syndrome * mmse \< 23 * circadian rhythm problems * sleep apnea syndrome * manifested or acute psychiatric comorbidities * pregnant women